newsfilter
← Latest News
Earnings Call Transcripts·

Inhibikase Therapeutics, Inc. at Jefferies Global Healthcare Conference in London - INHIBIKASE THERAPEUTICS INC

  • Financial Performance:

    • No specific revenue, earnings, or profit margin figures disclosed; company is in clinical development phase (Phase 3) with no commercial sales.
    • Cash & Runway: Sufficient cash runway projected to support trials through mid-2029 (completion of Part B).
    • Financing: Secured a $55 million financing tranche triggered by a Data Safety Monitoring Board (DSMB) safety update requiring 50 patients and 12 weeks of data.
  • Guidance and Future Outlook:

    • 2027: Release of blinded safety update (50 patients, 12 weeks) to satisfy financing conditions.
    • Mid-2028: Primary data readout for Part A (140 patients), focusing on Pulmonary Vascular Resistance (PVR) as primary endpoint; six-minute walk test (6MWT) data expected but not powered for significance.
    • Mid-2029: Pivotal data readout for Part B (targeting 340 patients total), intended for regulatory filing.
    • Long-term: Patents on new chemical entity (NCE) extend to 2039, with use patents until 2044.
    • Expansion: Preclinical studies for Group 2 and 3 Pulmonary Hypertension (PH) expected in 2027.
  • Business Segments and Product Lines:

    • Core Asset (IKT001): A pro-drug kinase inhibitor delivering Imatinib, designed to treat Pulmonary Arterial Hypothesis (PAH).
    • Differentiation: Unlike Novartis's IMPRESS trial, IKT001 utilizes a GI-protective pro-drug formulation to minimize nausea/vomiting and employs an 8-week slow titration (vs. 2 weeks) to improve tolerability.
    • Dosing Strategy: Targets doses of 300mg, 400mg, and 500mg; aims to match Imatinib efficacy (20–30% PVR reduction) with improved safety.
    • Combination Potential: Preclinical data supports synergy with Sotatercept; oral once-daily formulation expected to be used as second-line therapy or potentially in early starting regimens alongside PDE5 inhibitors and ERAs.
  • Market and Competitive Landscape:

    • Market Shift: PAH treatment paradigm is moving from vasodilators to antiproliferative agents (e.g., Sotatercept).
    • Unmet Need: Market requires multiple antiproliferative options; current vasodilators have limited ability to alter long-term disease course.
    • Competition: Acknowledges Sotatercept as a leader; notes that a competitor's NDA acceptance could broaden FDA confidence intervals for PAH data sets, benefiting all entrants.
    • Competitive Advantage: IKT001 offers an oral, once-daily alternative to injectables, aiming for a clinical profile comparable or superior to Sotatercept with better tolerability regarding GI side effects.
  • Risks and Challenges:

    • Trial Complexity: Managing small sample sizes (25 per arm) in the initial safety readout limits data depth; reliance on DSMB blind data.
    • Safety Concerns: Historical Imatinib issues with GI toxicity (nausea/vomiting) and edema mischaracterization as clinical worsening; mitigation involves novel formulation and refined investigator training.
    • Efficacy Variance: Risk of not achieving the "30-30" (30% PVR reduction, 30m 6MWT improvement) benchmark seen in older IMPRESS data; 20% reduction considered a "fantastic" baseline success.
    • Timing: Significant time lag before data availability (12–18 months to next catalyst).
  • Management Commentary and Tone:

    • Tone: Highly confident, optimistic, and proactive regarding trial execution (28 countries, 79 sites).
    • Confidence: Management asserts the pro-drug technology addresses Imatinib's historical failure points (GI toxicity) and that investigators are better educated on managing edema compared to the IMPRESS era.
    • Strategic Clarity: Emphasizes the "win-win" nature of a competitor's potential approval (expanding the market/standard of care) while positioning IKT001 as a superior oral option.
  • Analyst Questions and Answers:

    • Disclosure Limits: Q: Will blinded PVR data be released in 2027? A: Management will strictly adhere to the $55M financing obligation (DSMB confirmation) rather than disclosing small-sample PVR data.
    • Baseline PVR: Q: Is a 1,000 dyne baseline necessary? A: No; inclusion criteria target mid-700s PVR, citing recent Alexander Rothman study data showing efficacy at lower baselines.
    • 6MWT Significance: Q: Will Part A data show statistical significance for 6MWT? A: Unlikely due to sample size; Part B (larger cohort) is required for statistical power.
    • Regulatory Strategy: Q: How does a competitor's NDA impact IKT001? A: A competitor's approval validates the antiproliferative approach; IKT001 aims to leverage this with an oral, better-tolerated profile.
  • Other Key Points:

    • Regulatory Path: Utilizing FDA 505(b)(2) strategy, shaving ~3 years off the development timeline compared to sequential Phase 2b/3 approaches.
    • Mechanism of Action: IKT001 remains intact in the GI tract (avoiding c-KIT inhibition there, reducing GI side effects) and converts to free Imatinib in plasma for systemic efficacy.
    • Investor Relations: Company is transparent about the "long wait" for data but emphasizes consistent delivery of preclinical and safety milestones to maintain investor engagement.
Company
INHIBIKASE THERAPEUTICS INC
Keywords
INHIBIKASE THERAPEUTICS INC